A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Study Phase: Phase 2
Recruitment Status: Recruiting
Start Date: April 19, 2022
End Date: August 28, 2025
Global Biogen Clinical Trial Center
Inclusion Criteria:
- Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of age at the time of diagnosis
- Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening
- MDS-UPDRS Parts II and III (in OFF state) combined score less than or equal to (≤)40 at screening Key
Exclusion Criteria:
- Clinically significant neurological disorder other than PD, including but not limited to stroke, dementia, or seizure, within 5 years of screening visit, in the opinion of the Investigator
- Clinical evidence of atypical parkinsonism (e.g., multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
- Montreal Cognitive Assessment (MoCA) score <24 at the screening visit. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
-
Conditions:
- Parkinson Disease